Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

(MedPage Today) -- Progression-free survival (PFS) improved in advanced HER2-mutant non-small cell lung cancer (NSCLC) when treatment started with trastuzumab deruxtecan (T-DXd; Enhertu) instead of pembrolizumab (Keytruda) and chemotherapy, a large...

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Wednesday 16 September →